Results of a small study suggest that clemastine, a drug used to treat allergies, may repair damage to myelin in the optic nerve of people with MS.
The study used visual evoked potentials to measure the speed at which nerve impulses travelled from the eye to the visual cortex at the back of the brain. When the myelin coating of the optic nerve is damaged, the nerve impulse is slowed down.
Treatment with clemastine resulted in a small improvement in the speed of the nerve impulse. The researchers interpret this as showing repair to the damaged myelin coating of the optic nerve. The results suggest an improvement in vision, but the numbers involved were too small for this to be conclusive. The researchers were unable to show the repair on MRI scans and other measures of myelin.
Clemastine treatment was associated with fatigue, but no serious side effects were reported.
The dose used in the study was larger than normally used for allergies.
The researchers warn that more research with larger numbers of people is needed to better understand the role clemastine may play as a treatment for people with MS.
- Lancet 2017; Oct 10:1-9 [Epub ahead of print] Read the full paper Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.
Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.
Mayzent (siponimod) use expanded in England for secondary progressive multiple sclerosis
03/05/2022 - 00:00
NHS England has agreed that Mayzent can be prescribed for people with active secondary progressive multiple sclerosis whose disability has increased for at least 6 months, unrelated to relapses, and while taking a disease modifying drug.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.